Cognition Therapeutics In... (CGTX)
NASDAQ: CGTX
· Real-Time Price · USD
2.61
0.02 (0.77%)
At close: Sep 05, 2025, 3:59 PM
2.60
-0.38%
After-hours: Sep 05, 2025, 07:55 PM EDT
0.77% (1D)
| Bid | 2.51 |
| Market Cap | 191.76M |
| Revenue (ttm) | 250K |
| Net Income (ttm) | -32.99M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -3.95 |
| Forward PE | -9.25 |
| Analyst | Buy |
| Ask | 2.61 |
| Volume | 4,603,922 |
| Avg. Volume (20D) | 10,859,332 |
| Open | 2.64 |
| Previous Close | 2.59 |
| Day's Range | 2.42 - 2.67 |
| 52-Week Range | 0.22 - 3.83 |
| Beta | 1.33 |
About CGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-18.95%
Cognition Therapeutics shares are trading lower af...
Unlock content with
Pro Subscription
3 weeks ago
+10.91%
Cognition Therapeutics shares are trading higher after the company announced FDA confirmation of its Phase 3 trial design for Alzheimer's drug Zervimesine.
